Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: height (116), altitude (5), rise (125), increase (1000)

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/k
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Ipilimumab Ver 1

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Nivolumab-Relatlimab

Description: Chemotherapy Protocol SKIN CANCER Nivolumab in combination with Relatlimab (Opdualag) Regimen • Skin – Nivolumab in in combination wit
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-Relatlimab-Ver1.pdf

Endometrial-Dostarlimab

Description: Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Binimetinib-Encorafenib

Description: Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or metastatic BRAF V600 mutation-positive melanoma where the following co
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

Gemcitabine

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEMCITABINE Regimen NSCLC - Gemcitabine Indication Second line therapy of stage III or IV NSCLC WHO Performance status 0, 1, 2 Palliative int
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gemcitabinever12.pdf

Carboplatin(AUC6)-Gemcitabine

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC6)-GEMCITABINE Regimen  NSCLC – Carboplatin (AUC6)-Gemcitabine Indication  First line therapy of stage III or IV NSCLC  WHO Performance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-AUC6-Gemcitabine.pdf

Asciminib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Asciminib Regimen • Asciminib Indication • Patients with chronic phase Philadelphia chromo
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Asciminib.pdf

Cisplatin and Gemcitabine

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-GEMCITABINE Regimen NSCLC – Cisplatin-Gemcitabine Indication Non-small cell lung cancer (in particular non-adenocarcinoma) Thymic carcinoma (in p
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandGemcitabinever12.pdf

21 to 30 of 104

Previous 1 2 3 4 5 … Next